176 related articles for article (PubMed ID: 33923724)
21. A potential therapeutic neutralization monoclonal antibody specifically against multi-coxsackievirus A16 strains challenge.
Du R; Mao Q; Hu Y; Lang S; Sun S; Li K; Gao F; Bian L; Yang C; Cui B; Xu L; Cheng T; Liang Z
Hum Vaccin Immunother; 2019; 15(10):2343-2350. PubMed ID: 30735461
[TBL] [Abstract][Full Text] [Related]
22. Development of sandwich ELISAs that can distinguish different types of coxsackievirus A16 viral particles.
Ye X; Yang L; Jia J; Han J; Li S; Liu Y; Xu L; Zhao H; Chen Y; Li Y; Cheng T; Xia N
Appl Microbiol Biotechnol; 2016 Mar; 100(6):2809-15. PubMed ID: 26767830
[TBL] [Abstract][Full Text] [Related]
23. The Bottlenecks of Preparing Virus Particles by Size Exclusion for Antibody Generation.
Lee CH; Huang PN; Mwale PF; Wang WC; Leu SJ; Tseng SN; Shih SR; Chiang LC; Mao YC; Tsai BY; Dlamini NB; Nguyen TC; Tsai CH; Yang YY
Int J Mol Sci; 2022 Oct; 23(21):. PubMed ID: 36361757
[TBL] [Abstract][Full Text] [Related]
24. Protection from lethal challenge in a neonatal mouse model by circulating recombinant form coxsackievirus A16 vaccine candidates.
Li J; Chang J; Liu X; Yang J; Guo H; Wei W; Zhang W; Yu XF
J Gen Virol; 2014 May; 95(Pt 5):1083-1093. PubMed ID: 24496826
[TBL] [Abstract][Full Text] [Related]
25. Cross-reactivity of anti-EV71 IgM and neutralizing antibody in series sera of patients infected with Enterovirus 71 and Coxsackievirus A 16.
Lin Y; Wen K; Pan Y; Wang Y; Che X; Wang B
J Immunoassay Immunochem; 2011; 32(3):233-43. PubMed ID: 21574094
[TBL] [Abstract][Full Text] [Related]
26. Hand, foot and mouth disease: seroprevalence of Coxsackie A16 and Enterovirus 71 in Germany.
Rabenau HF; Richter M; Doerr HW
Med Microbiol Immunol; 2010 Feb; 199(1):45-51. PubMed ID: 19941005
[TBL] [Abstract][Full Text] [Related]
27. Coxsackievirus A16-like particles produced in Pichia pastoris elicit high-titer neutralizing antibodies and confer protection against lethal viral challenge in mice.
Zhang C; Liu Q; Ku Z; Hu Y; Ye X; Zhang Y; Huang Z
Antiviral Res; 2016 May; 129():47-51. PubMed ID: 26902108
[TBL] [Abstract][Full Text] [Related]
28. Development of a coxsackievirus A16 neutralization test based on the enzyme-linked immunospot assay.
Hou W; Yang L; He D; Zheng J; Xu L; Liu J; Liu Y; Zhao H; Ye X; Cheng T; Xia N
J Virol Methods; 2015 Apr; 215-216():56-60. PubMed ID: 25704596
[TBL] [Abstract][Full Text] [Related]
29. Phage Display-Derived Cross-Reactive Neutralizing Antibody against Enterovirus 71 and Coxsackievirus A16.
Zhang X; Sun C; Xiao X; Pang L; Shen S; Zhang J; Cen S; Yang BB; Huang Y; Sheng W; Zeng Y
Jpn J Infect Dis; 2016; 69(1):66-74. PubMed ID: 26073737
[TBL] [Abstract][Full Text] [Related]
30. [Detection of enterovirus 71 and coxsackievirus A16 from children with hand, foot and mouth disease in Shanghai, 2002].
Yang ZH; Zhu QR; Li XZ; Wang XH; Wang JS; Hu JY; Tang W; Cui AL
Zhonghua Er Ke Za Zhi; 2005 Sep; 43(9):648-52. PubMed ID: 16191294
[TBL] [Abstract][Full Text] [Related]
31. A Broadly Cross-protective Vaccine Presenting the Neighboring Epitopes within the VP1 GH Loop and VP2 EF Loop of Enterovirus 71.
Xu L; He D; Yang L; Li Z; Ye X; Yu H; Zhao H; Li S; Yuan L; Qian H; Que Y; Kuo Shih JW; Zhu H; Li Y; Cheng T; Xia N
Sci Rep; 2015 Aug; 5():12973. PubMed ID: 26243660
[TBL] [Abstract][Full Text] [Related]
32. Coxsackievirus A16: epidemiology, diagnosis, and vaccine.
Mao Q; Wang Y; Yao X; Bian L; Wu X; Xu M; Liang Z
Hum Vaccin Immunother; 2014; 10(2):360-7. PubMed ID: 24231751
[TBL] [Abstract][Full Text] [Related]
33. Cost-effectiveness of bivalent versus monovalent vaccines against hand, foot and mouth disease.
Liu D; Leung K; Jit M; Yu H; Yang J; Liao Q; Liu F; Zheng Y; Wu JT
Clin Microbiol Infect; 2020 Mar; 26(3):373-380. PubMed ID: 31279839
[TBL] [Abstract][Full Text] [Related]
34. Coxsackievirus A 16 infection does not interfere with the specific immune response induced by an enterovirus 71 inactivated vaccine in rhesus monkeys.
Wang J; Qi S; Zhang X; Zhang Y; Liu L; Che Y; He Z; Zhao Y; Lu S; Yu W; Li Q
Vaccine; 2014 Jul; 32(35):4436-4442. PubMed ID: 24958699
[TBL] [Abstract][Full Text] [Related]
35. The immunogenicity and protection effect of an inactivated coxsackievirus A6, A10, and A16 vaccine against hand, foot, and mouth disease.
Lim H; In HJ; Lee JA; Sik Yoo J; Lee SW; Chung GT; Choi YK; Chung JK; Cho SJ; Lee JW
Vaccine; 2018 Jun; 36(24):3445-3452. PubMed ID: 29739716
[TBL] [Abstract][Full Text] [Related]
36. Immunity to avirulent enterovirus 71 and coxsackie A16 virus protects against enterovirus 71 infection in mice.
Wu TC; Wang YF; Lee YP; Wang JR; Liu CC; Wang SM; Lei HY; Su IJ; Yu CK
J Virol; 2007 Oct; 81(19):10310-5. PubMed ID: 17626076
[TBL] [Abstract][Full Text] [Related]
37. Canine Parvovirus is diagnosed and neutralized by chicken IgY-scFv generated against the virus capsid protein.
Ge S; Xu L; Li B; Zhong F; Liu X; Zhang X
Vet Res; 2020 Sep; 51(1):110. PubMed ID: 32883344
[TBL] [Abstract][Full Text] [Related]
38. A new EV71 VP3 epitope in norovirus P particle vector displays neutralizing activity and protection in vivo in mice.
Jiang L; Fan R; Sun S; Fan P; Su W; Zhou Y; Gao F; Xu F; Kong W; Jiang C
Vaccine; 2015 Nov; 33(48):6596-603. PubMed ID: 26529072
[TBL] [Abstract][Full Text] [Related]
39. Enterovirus type 71-immunized chicken egg yolk immunoglobulin has cross antiviral activity against coxsackievirus A16
Gao E; Wu S; Xu Q; Zeng Y; Tan N; He S; Yang Y; Wei J
Exp Ther Med; 2019 Jul; 18(1):332-341. PubMed ID: 31258670
[TBL] [Abstract][Full Text] [Related]
40. Dynamic change of mother-source neutralizing antibodies against enterovirus 71 and coxsackievirus A16 in infants.
Mao QY; Liao XY; Yu X; Li N; Zhu FC; Zeng Y; Liang ZL; Li FX; Wang JZ; Lu FM; Zhuang H
Chin Med J (Engl); 2010 Jul; 123(13):1679-84. PubMed ID: 20819628
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
